Illumina Reports Financial Results for Third Quarter of Fiscal Year 2026
Illumina reported Q3 2026 revenue of $1.13B, up 4.2% YoY. GAAP EPS was $1.43. The company raised full-year revenue guidance to $4.64B-$4.66B and EPS guidance to $5.40-$5.45, citing strong clinical demand and NovaSeq X placements. Cash flow from operations was $419M, with free cash flow at $378M.
How this was made
The 30-second read
Why it matters
The raised guidance signals stronger market demand and may trigger re‑rating by analysts.
Market read
Earnings beat and guidance lift are likely to move Illumina's stock and influence related biotech equities.
What to watch
Potential regulatory risk in China and tariff uncertainties could temper upside.
Background
Illumina is a leading provider of DNA sequencing systems; its results are closely watched for biotech sector health.
Ticker impact
Illumina released Q3 FY2026 results and raised full‑year revenue and EPS guidance.
likely upward pressure as investors price in higher revenue and earnings outlook
Revenue guidance increased to $4.64‑$4.66B and EPS to $5.40‑$5.45, both above prior guidance, indicating improved performance.
Market effects
May lift other genomics and biotech stocks as the sector benefits from higher demand for sequencing.
Positive for US biotech listings; limited direct effect elsewhere.
Reinforces optimism for global life‑science investors tracking Illumina's AI‑driven platform.
Counterpoint
If the guidance raise is already priced in, any short‑term pull‑back could present a buying opportunity.
Key entities
- ExecutiveJacob Thaysen
CEO of Illumina, quoted on results and outlook.
